has been cited by the following article(s):
[1]
|
How excluding some benefits from value assessment of new drugs impacts innovation
Health Economics,
2017
DOI:10.1002/hec.3507
|
|
|
[2]
|
How excluding some benefits from value assessment of new drugs impacts innovation
Health Economics,
2017
DOI:10.1002/hec.3507
|
|
|
[3]
|
How Excluding Some Benefits from Value Assessment of New Medicines Impacts Innovation
SSRN Electronic Journal,
2015
DOI:10.2139/ssrn.2608791
|
|
|
[4]
|
Taring All Investors with the Same Brush? Evidence for Heterogeneity in Individual Preferences from a Maximum Likelihood Approach
SSRN Electronic Journal ,
2015
DOI:10.2139/ssrn.2845866
|
|
|
[5]
|
On the Applicability of Maximum Likelihood Methods: From Experimental to Financial Data
SSRN Electronic Journal,
2013
DOI:10.2139/ssrn.2845871
|
|
|